1335214-45-3Relevant academic research and scientific papers
Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues
Zhmurov, Petr A.,Sukhorukov, Alexey Yu.,Chupakhin, Vladimir I.,Khomutova, Yulia V.,Ioffe, Sema L.,Tartakovsky, Vladimir A.
, p. 8082 - 8091 (2013/12/04)
Asymmetric syntheses of two of GlaxoSmithKline's highly potent phosphodiesterase IV inhibitors CMPI 1 and CMPO 2 have been accomplished from nitroethane and simple precursors in 8 and 7 steps, respectively. The suggested synthetic strategy involves as a key stage the silylation of enantiopure six-membered cyclic nitronates. In vitro studies of PDE IVB1 inhibition revealed a significant difference in the activity of CMPI 1 and CMPO 2 enantiomers.
Synthesis of PDE IVb Inhibitors. 1. asymmetric synthesis and stereochemical assignment of (+)- and (-)-7-[3-(Cyclopentyloxy)-4-methoxyphenyl]hexahydro-3H- pyrrolizin-3-one
Sukhorukov, Alexey Yu.,Boyko, Yaroslav D.,Ioffe, Sema L.,Khomutova, Yulia A.,Nelyubina, Yulia V.,Tartakovsky, Vladimir A.
, p. 7893 - 7900 (2011/11/30)
Asymmetric synthesis of Glaxo Smith Kline's highly potent phosphodiesterase inhibitor 1 has been accomplished in nine steps and 16% overall yield. The original strategy suggested involves as a key step the silylation of enantiopure six-membered cyclic nit
